Exelixis Inc (EXEL)

Add to Watchlists
Create an Alert
Quickflows
21.82 -0.02  -0.09% NASDAQ Oct 15, 16:00 21.83 +0.01  +0.05% After-Hours: 20:00 USD
View Full Chart
Price Chart
View All Key Stats

Key Stats

View All EXEL News

News

View All Events

Events

Date Type Description
11/05/2021 Earnings Results Q3 2021 Earnings Results
11/05/2021 17:00 EST Earnings Calls Q3 2021 Earnings Call
08/05/2021 Earnings Results Q2 2021 Earnings Results
08/05/2021 17:00 EST Earnings Calls Q2 2021 Earnings Call
05/26/2021 12:00 EST AGM 2021 Annual General Meeting
05/06/2021 Earnings Results Q1 2021 Earnings Results
05/06/2021 17:00 EST Earnings Calls Q1 2021 Earnings Call
02/10/2021 Earnings Results Q4 2020 Earnings Results
02/10/2021 17:00 EST Earnings Calls Q4 2020 Earnings Call
11/05/2020 Earnings Results Q3 2020 Earnings Results
View All Performance Charts

Total Returns Comparison

Fundamentals

Income Statement View Statement

Revenue (TTM) 1.157B
Total Expenses (TTM) 1.056B
Net Income (TTM) 94.04M

Balance Sheet View Statement

Total Assets (Quarterly) 2.367B
Total Liabilities (Quarterly) 324.19M
Shareholders Equity (Quarterly) 2.043B

Cash Flow Statement View Statement

Cash from Operations (TTM) 272.28M
Cash from Investing (TTM) -245.70M
Cash from Financing (TTM) -16.06M

Ratings & Reports

Advertisement
Edit

Profile

  • Description: Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule cabozantinib is indicated for the treatment of patients with metastatic medullary thyroid cancer (as Cometriq) and advanced renal cell carcinoma, or kidney cancer, and hepatocellular carcinoma, or liver cancer (as Cabometyx). Exelixis and partner Roche have also brought Cotellic to market for the treatment of melanoma.
  • URL: https://www.exelixis.com
  • Investor Relations URL: https://ir.exelixis.com
  • HQ State/Province: California
  • Sector: Healthcare
  • Industry: Biotechnology
  • Equity Style: Small Cap/Growth
  • Next Earnings Release: Nov. 05, 2021
  • Last Earnings Release: Aug. 05, 2021
  • Next Ex-Dividend Date: N/A
  • Last Ex-Dividend Date: N/A

Analyst Coverage

Consensus Recommendations
Buy Recommendations Upgrade
Outperform Recommendations Upgrade
Hold Recommendations Upgrade
Underperform Recommendations Upgrade
Sell Recommendations Upgrade
Consensus Recommendation Upgrade
Consensus Rating Upgrade
Target Price
Price 21.82
Price Target Upgrade
Price Target Upside (Daily) Upgrade

Top Fund Holders

Symbol Name Weighting
FBT First Trust NYSE Arca Biotech ETF 4.34%
VLLIX Value Line Larger Companies Focus Instl 4.08%
IDNA iShares Genomics Immnlgy & Hlthcr ETF 3.71%
VLIIX Value Line Capital Appreciation Instl 3.49%
PBE Invesco Dynamic Biotech & Genome ETF 3.23%
FIJYX Fidelity Advisor® Biotechnology Z 2.57%
FTZCX Fuller & Thaler Behvrll Uncnstd Eq C 1.98%
BBP Virtus LifeSci Biotech Products ETF 1.92%
RLSMX Lazard US Small-Mid Cap Equity R6 1.40%
XBI SPDR® S&P Biotech ETF 0.84%
LABU Direxion Daily S&P Biotech Bull 3X ETF 0.54%
JMEZX JPMorgan Market Expansion Enh Idx R2 0.47%

Comparables

Edit
BMY Bristol-Myers Squibb Co
NVAX Novavax Inc
VRTX Vertex Pharmaceuticals Inc
INCY Incyte Corp
INO Inovio Pharmaceuticals Inc

Other Resources

Advertisement

{{root.upsell.info.feature_headline}}.

{{root.upsell.info.feature_description}}

Please note that this feature is only available as an add-on to YCharts subscriptions.

Please note that this feature requires full activation of your account and is not permitted during the free trial period.

Start My Free Trial {{root.upsell.info.call_to_action}} No credit card required.

Already a subscriber? Sign in.